Health Care & Life Sciences » Pharmaceuticals | Zhejiang Starry Pharmaceutical Co. Ltd.

Zhejiang Starry Pharmaceutical Co. Ltd. A | Cash Flow

Fiscal year is January-December. All values CNY Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
62,799.70
67,026.00
73,466.50
75,905.60
81,425.00
95,539.20
Depreciation, Depletion & Amortization
44,424.80
51,711.40
58,730.20
66,599.60
74,058.70
87,320.70
Other Funds
28,201.20
30,927.70
38,944.60
280,553.80
52,615.30
65,855.60
Funds from Operations
135,574.90
146,263.50
171,989.70
163,707.80
182,355.60
246,685.40
Changes in Working Capital
60,177.50
2,148.00
76,902.90
155,530.40
162,226.40
53,049.80
Net Operating Cash Flow
75,397.40
144,115.50
95,086.70
8,177.50
20,129.20
193,635.60
Capital Expenditures
188,422.10
206,760.80
244,655.10
188,510.60
76,676.20
Sale of Fixed Assets & Businesses
189.40
45,930.50
3,811.80
198.20
11,049.50
Purchase/Sale of Investments
-
-
-
87,109.90
80,997.40
Net Investing Cash Flow
184,602.70
160,830.30
240,843.30
265,061.60
15,370.70
Cash Dividends Paid - Total
13,500.00
27,000.00
49,500.00
36,000.00
36,000.00
Issuance/Reduction of Debt, Net
144,449.50
72,004.30
305,158.60
51,516.70
99,268.40
Net Financing Cash Flow
102,748.30
14,076.60
216,714.00
296,070.50
10,653.10
Net Change in Cash
5,438.00
2,789.50
72,085.30
41,995.60
42,615.80
Free Cash Flow
113,024.70
62,645.40
149,568.40
180,333.20
56,547.00
Deferred Taxes & Investment Tax Credit
5.40
767.70
1,911.80
932.20
59.70
2,030.20
Other Sources
3,630.00
-
-
10,360.80
-
Exchange Rate Effect
1,019.00
151.30
1,127.80
2,809.30
3,537.20

About Zhejiang Starry Pharmaceutical Co.

View Profile
Address
9 Fengxi West Road
Taizhou Zhejiang 317306
China
Employees -
Website http://www.starrypharm.com
Updated 07/08/2019
Zhejiang Starry Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of active ingredient and intermediate X-CT non-ionic contrast agent and fluoroquinolones series. Its products include fluorine quinoline derivatives, carbapenem, iohexol, ioversol, iopamidol, iopromide, iodixanol, levofloxacin, levofloxacin hydrochloride, levofloxacin acid ester, levofloxacin acid, pazufloxacin, pazufloxacin mesylate, meropenem, faropenem sodium, iomeprol, and gadobenate dimeglumine. The company was founded on September 15, 1997 and is headquartered in Taizhou, China.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.